Compare GBDC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBDC | RCUS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2009 | 2018 |
| Metric | GBDC | RCUS |
|---|---|---|
| Price | $13.22 | $29.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $14.38 | ★ $31.90 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.69% | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | $45.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.77 | $10.07 |
| 52 Week High | $14.93 | $31.74 |
| Indicator | GBDC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 56.83 |
| Support Level | $12.70 | $25.94 |
| Resistance Level | $13.45 | $31.41 |
| Average True Range (ATR) | 0.23 | 1.20 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 70.00 | 62.68 |
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.